Cargando…

Skin Involvement in Psoriatic Arthritis Worsens Overall Disease Activity, Patient-Reported Outcomes, and Increases Healthcare Resource Utilization: An Observational, Cross-Sectional Study

INTRODUCTION: Psoriatic arthritis (PsA) is an inflammatory arthropathy that exhibits heterogeneity in clinical presentation and severity of skin and joint symptoms. This heterogeneity results in an incomplete understanding of the relationship between the skin and joint components of PsA, and their r...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Vlam, Kurt, Merola, Joseph F., Birt, Julie A., Sandoval, David M., Lobosco, Steve, Moon, Rachel, Milligan, Gary, Boehncke, Wolf-Henning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251843/ https://www.ncbi.nlm.nih.gov/pubmed/29980935 http://dx.doi.org/10.1007/s40744-018-0120-8

Ejemplares similares

Disease Characteristics and the Burden of Joint and Skin Involvement Amongst People With Psoriatic Arthritis: A Population Survey
por: Tillett, William, et al.
Publicado: (2020)

Treatment recommendations for psoriatic arthritis
por: Ritchlin, C T, et al.
Publicado: (2009)

Evolution of psoriatic arthritis study patient population characteristics in the era of biological treatments
por: Vandendorpe, Ann-Sophie, et al.
Publicado: (2019)

Patient Perspective on the Burden of Skin and Joint Symptoms of Psoriatic Arthritis: Results of a Multi-National Patient Survey
por: Merola, Joseph F., et al.
Publicado: (2019)

Orthopaedic interventions in patients with psoriatic arthritis: a descriptive report from the SPAR cohort
por: Haque, Naba, et al.
Publicado: (2016)

LOOP, a cross-sectional, observational study investigating the clinical specialty setting as a determinant of disease management in psoriatic arthritis: Subgroup analysis results from Japan
por: Okada, Masato, et al.
Publicado: (2021)

Systematic review of the use of CRP in clinical trials for psoriatic arthritis: a concern for clinical practice?
por: Houttekiet, Charlotte, et al.
Publicado: (2022)

Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2022)

Triple jump for the optimal management of psoriatic arthritis: diet, sleep and exercise – a review
por: Lubrano, Ennio, et al.
Publicado: (2023)

Mechanotransduction in Skin Inflammation
por: Shutova, Maria S., et al.
Publicado: (2022)

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
por: Mease, Philip J, et al.
Publicado: (2021)

Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health‐related quality of life from two randomized phase 3 studies
por: Merola, J.F., et al.
Publicado: (2020)

Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis
por: Helliwell, Philip, et al.
Publicado: (2014)

Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis
por: Ogdie, Alexis, et al.
Publicado: (2020)

Autoreactive T-Lymphocytes in Inflammatory Skin Diseases
por: Boehncke, Wolf-Henning, et al.
Publicado: (2019)

The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies
por: Kavanaugh, Arthur, et al.
Publicado: (2019)

Mitogen-activated kinases in psoriatic arthritis: differences in activation and distinct regulation by etanercept therapy
por: Lories, RJU, et al.
Publicado: (2005)

Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis
por: de Vlam, Kurt, et al.
Publicado: (2022)

Distinguishing rheumatoid arthritis from psoriatic arthritis
por: Merola, Joseph F, et al.
Publicado: (2018)

Evolution of patient characteristics in the era of biologic treatment of psoriatic arthritis: 18-year Belgian experience from the Leuven Spondyloarthritis Biologics Cohort (BioSPAR)
por: Ishchenko, Alla, et al.
Publicado: (2021)

Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial
por: Helliwell, Philip S., et al.
Publicado: (2020)

Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
por: Elewski, Boni E., et al.
Publicado: (2022)

Extent of axial damage in psoriatic arthritis and spondyloarthritis: comparative data from the BEPAS and (Be-)GIANT multicentre cohorts
por: de Hooge, Manouk, et al.
Publicado: (2023)

Promoting patient‐centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience
por: Betteridge, N., et al.
Publicado: (2015)

Reduced TRPC Channel Expression in Psoriatic Keratinocytes Is Associated with Impaired Differentiation and Enhanced Proliferation
por: Leuner, Kristina, et al.
Publicado: (2011)

Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis
por: Olejniczak-Staruch, Irmina, et al.
Publicado: (2021)

Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study
por: Stouten, Veerle, et al.
Publicado: (2021)

Improved patient-reported outcomes in patients with psoriatic arthritis treated with risankizumab: analysis of the Phase 3 trial KEEPsAKE 2
por: Ostor, Andrew J K, et al.
Publicado: (2022)

Delayed Diagnosis of Psoriatic Arthritis Mutilans due to Arthritis Prior to Skin Lesion
por: Mochizuki, Takeshi, et al.
Publicado: (2018)

Median time to pain improvement and the impact of baseline pain severity on pain response in patients with psoriatic arthritis treated with tofacitinib
por: de Vlam, Kurt, et al.
Publicado: (2021)

Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis
por: Gladman, Dafna, et al.
Publicado: (2020)

Psoriatic arthritis
por: Sankowski, Artur Jacek, et al.
Publicado: (2013)

Psoriatic Arthritis
por: Fitzgerald, Kara, et al.
Publicado: (2012)

Psoriatic arthritis
por: Ocampo D, Vanessa, et al.
Publicado: (2019)

Pain Medication and Corticosteroid Use in Ankylosing Spondylitis, Psoriatic Arthritis, and Rheumatoid Arthritis in the United States: A Retrospective Observational Study
por: Hunter, Theresa, et al.
Publicado: (2021)

Real-World Efficacy and Safety of Apremilast in Belgian Patients with Psoriatic Arthritis: Results from the Prospective Observational APOLO Study
por: de Vlam, Kurt, et al.
Publicado: (2022)

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
por: Gossec, Laure, et al.
Publicado: (2020)

A Threshold of Meaning for Work Disability Improvement in Psoriatic Arthritis Measured by the Work Productivity and Activity Impairment Questionnaire
por: Tillett, William, et al.
Publicado: (2019)

Musculoskeletal Imaging for Dermatologists: Techniques in the Diagnosis and Management of Psoriatic Arthritis
por: Gottlieb, Alice B., et al.
Publicado: (2021)

Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
por: Ritchlin, Christopher T, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vg1oqf9chipmfc35378vvmepqs